Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
MSH3 DUC1, DUG
Sequence Length (AA) Molecular Weight (Da)
1137 127412
Protein Name
DNA mismatch repair protein Msh3
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MSRRKPASGG LAASSSAPAR QAVLSRFFQS TGSLKSTSSS TGAADQVDPG
60 70 80 90 100
AAAAAAAAAA AAPPAPPAPA FPPQLPPHIA TEIDRRKKRP LENDGPVKKK
110 120 130 140 150
VKKVQQKEGG SDLGMSGNSE PKKCLRTRNV SKSLEKLKEF CCDSALPQSR
160 170 180 190 200
VQTESLQERF AVLPKCTDFD DISLLHAKNA VSSEDSKRQI NQKDTTLFDL
210 220 230 240 250
SQFGSSNTSH ENLQKTASKS ANKRSKSIYT PLELQYIEMK QQHKDAVLCV
260 270 280 290 300
ECGYKYRFFG EDAEIAAREL NIYCHLDHNF MTASIPTHRL FVHVRRLVAK
310 320 330 340 350
GYKVGVVKQT ETAALKAIGD NRSSLFSRKL TALYTKSTLI GEDVNPLIKL
360 370 380 390 400
DDAVNVDEIM TDTSTSYLLC ISENKENVRD KKKGNIFIGI VGVQPATGEV
410 420 430 440 450
VFDSFQDSAS RSELETRMSS LQPVELLLPS ALSEQTEALI HRATSVSVQD
460 470 480 490 500
DRIRVERMDN IYFEYSHAFQ AVTEFYAKDT VDIKGSQIIS GIVNLEKPVI
510 520 530 540 550
CSLAAIIKYL KEFNLEKMLS KPENFKQLSS KMEFMTINGT TLRNLEILQN
560 570 580 590 600
QTDMKTKGSL LWVLDHTKTS FGRRKLKKWV TQPLLKLREI NARLDAVSEV
610 620 630 640 650
LHSESSVFGQ IENHLRKLPD IERGLCSIYH KKCSTQEFFL IVKTLYHLKS
660 670 680 690 700
EFQAIIPAVN SHIQSDLLRT VILEIPELLS PVEHYLKILN EQAAKVGDKT
710 720 730 740 750
ELFKDLSDFP LIKKRKDEIQ GVIDEIRMHL QEIRKILKNP SAQYVTVSGQ
760 770 780 790 800
EFMIEIKNSA VSCIPTDWVK VGSTKAVSRF HSPFIVENYR HLNQLREQLV
810 820 830 840 850
LDCSAEWLDF LEKFSEHYHS LCKAVHHLAT VDCIFSLAKV AKQGDYCRPT
860 870 880 890 900
VQEERKIVIK NGRHPVIDVL LGEQDQYVPN NTDLSEDSER VMIITGPNMG
910 920 930 940 950
GKSSYIKQVA LITIMAQIGS YVPAEEATIG IVDGIFTRMG AADNIYKGQS
960 970 980 990 1000
TFMEELTDTA EIIRKATSQS LVILDELGRG TSTHDGIAIA YATLEYFIRD
1010 1020 1030 1040 1050
VKSLTLFVTH YPPVCELEKN YSHQVGNYHM GFLVSEDESK LDPGAAEQVP
1060 1070 1080 1090 1100
DFVTFLYQIT RGIAARSYGL NVAKLADVPG EILKKAAHKS KELEGLINTK
1110 1120 1130 1137
RKRLKYFAKL WTMHNAQDLQ KWTEEFNMEE TQTSLLH

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-6246 Collapse assay details

Data source: Panorama

Official Gene Symbol
MSH3
Peptide Sequence
DLSDFPLIK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
7
Peptide Start
705
Peptide End
713
CPTAC ID
CPTAC-6246
Peptide Molecular Mass
1,046.5648
Species
Homo Sapiens
Assay Type
Enrichment MRM
Enrichment Method
Peptide Immunoaffinity
Matrix
Frozen tissue
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTRAP 5500
Internal Standard
Extended heavy peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent
Column Packing
Reprosil C18, 3um
Column Dimensions
75µm x 15cm
Flow Rate
0.3 µL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y6 (1+) 6.5 3.7 5.9 5.2 6.5 10.6 8.3 7.5 12.1 15 15 15
y7 (1+) 6.5 3 13.1 6.4 6.8 22.8 9.1 7.4 26.3 15 15 15
y5 (1+) 6.1 3 5.9 6.6 5.8 10.7 9 6.5 12.2 15 15 15
y4 (1+) 7.6 3.1 4.5 5.8 6.9 9.2 9.6 7.6 10.2 15 15 15
sum 6.2 2.6 8.8 5.4 5.8 16 8.2 6.4 18.3 15 15 15


Additional Resources and Comments